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Purpose: Non-steroidal anti-inflammatory drugs (NSAID)
are frequently used in oral surgical procedures in dentistry.
The evaluation of the frequency of sister chromatid exchange
(SCE) is accepted as a reliable cytogenetic method to assess
the genotoxic effects of environmental factors. Materials and
Methods: In this study, the genotoxic effects of various
NSAIDs were assessed in 30 patients to who they were
administered following encluosed third molar surgery using
SCE analysis before and after the operation. The frequency of
SCE was evaluated before the operation and after 3 days of
etodolac, nimesulid and naproxen use. Results: There was no
statistically significant difference in the frequency of SCE
between the preoperative and postoperative states in patients
given etodolac, nimesulid or naproxen sodium. Conclusion:
Short term use of selective and non-selective NSAIDs was not
associated with a significant genotoxic effect that could be
detected using the SCE method in peripheric lymphocytes.
Key Words: Genotoxicity, sister chromatid exchange, oral
surgery, non-steroidal anti-inflammatory drugs
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs)
have a wide range of indications in the treatment
of medical and surgical diseases due to their
analgesic, antipyretic and anti-inflammatory
effects.
1,2 They are frequently used in painful and
inflammatory conditions such as rheumatologic
diseases, orthopedic and gynecologic surgery and
in soft tissue traumas. This group of medications
is also commonly used in the clinical practice of
dentistry, such as in the treatment of oro-facial
pain or after oral surgical procedures.
3,4
Some NSAIDs are widely used in Turkey,
without prescription, for their analgesic and
anti-inflammatory properties.
Naproxen, a propionic acid derivative, is a
prototypical anti-inflammatory agent which is
generally used for the treatment of rheumatoid
arthritis, osteoarthritis, primary dysmenorrhea,
ankylosing spondylitis, bursitis, tendonitis,
juvenile arthritis, acute gout, fever, following
dental, obstetric or orthopedic surgery, for pro-
phylaxis and the treatment of vascular headaches.
The recommended adult dosage of naproxen
sodium for acute pain is 550 - 1,100 mg/day in
divided doses. If necessary, the dosage may be
increased up to 1,650 mg/day for a short period.
5
Etodolac is a pyranocarboxylic acid-derived
nonsteroidal anti-inflammatory drug (NSAID) that
possesses analgesic activity. Etodolac suppresses
the biosynthesis of prostaglandins by inhibition of
cyclcoxygenases such as other NSAIDs. Etodolac
is used in osteoarthritis, rheumatoid arthritis,
tendonitis, bursitis, acute sports injuries, gout,
pain of orthopedic pathologies, dysmenorrhea,
postoperative pain (surgical and dental procedures)
and for pain associated with non-rheumatic
inflammatory conditions or vascular headaches. A
dosage of 200 - 400 mgr every 6 to 8 hours is
recommended for acute pain.
3 Earlier studies have
reported that etodolac at 50 to 400 mg/day
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provided dose-related relief of moderate to severe
postoperative pain from a variety of surgical and
dental procedures.
6,7
Nimesulide is a sulfononilide nonsteroidal anti-
inflammatory drug with marked anti-inflamma-
tory, antipyretic and analgesic properties and is
indicated for osteoarthritis, rheumatoid arthritis,
reduction of fever, primary dysmenorrhea and for
relief of mild to moderate pain. The recommended
adult dosage of nimesulide is 100 mg administered
orally as tablets twice daily.
8
NSAIDs have severe toxic effects on the gastro-
intestinal and renal systems; central nervous
system, otic, ocular and adverse effects (pruritis,
skin eruptions, or rashes, ecchymoses, dermatitis,
sweeting and photosensitivity reactions). They can
cause gastric mucosal damage, which may result
in ulceration and/or bleeding, although they can
inhibit platelet aggregation and may prolong the
bleeding time but they do not effect the pro-
thrombin time or whole blood clotting time.
5 The
gastrointestinal and renal side effects of selective
COX2 inhibitors are claimed to be fewer than
those of the classical NSAIDs.
1,2 For that reason
their use has become more frequent in recent
times.
Studies on the genotoxic potential of these
drugs are limited. Various studies have shown
that they either have only a weak or no genotoxic
effect at all.
9-12
Enclosed third molar surgery is one of the most
common surgical interventions in oral surgery.
13
NSAIDs are given after the surgical operation to
prevent complaints and complications. Pharma-
cologic therapy plays a very important role in
acute inflammation. Patients want relief from
pain, so the most useful agents are those that
provide analgesic as well as anti-inflammatory
effects. Various drugs are commonly administered
in the postoperative period for the relief of pain
and oedema. For these patients, the drugs of
choice are NSAIDs which are widely used in
routine daily practice.
Analysis of the frequency of Sister Chromatid
Exchange (SCE) is a sensitive and reliable technique
for the detection of DNA damage caused by
various environmental factors, such as various
physical and chemical agents and drugs.
14-16
In this study, the genotoxic effects of three
commonly used NSAIDs were investigated using
the frequency of SCEs in peripheral lymphocytes
before and after drug use in patients undergoing
oral surgery.
MATERIALS AND METHODS
In this prospective study, thirty consequential
patients (male/female = 1, age:19 - 25 years, mean
age: 21.6 ± 1.90) for whom an enclused third molar
operation was planned were randomly and
blindly separated into 3 groups (etodolac, naproxen
sodium and nimesulid groups). The patients were
non-smokers and on no other medications at the
time of this study. Written and oral consents were
obtained from all of patients. The first peripheric
blood samples were obtained prior to commencing
therapy and the second after 3 days of NSAID
treatment. Patients were given either etodolac 800
mg/day, naproxen sodium 1,100 mg/day or
nimesulid 200 mgr/day in two divided doses.
Peripheric lymphocytes were cultured using a
modified procedure of the peripheric blood
culture method developed by Moorhead et al.
17 A
stock medium was prepared by the addition of
20% fetal bovine serum, 1% Penicilinle-strepto-
mycine, 1.5% PHA-M (PHA-M, Biochrom KG,
Berlin, Germany) and 1% L-glutamine to 100 mL
of Ham's F-10 medium (Biochrom KG, Berlin,
Germany). In each culture tube, 0.3 mL of the
blood sample, with heparin was added using a
sterile syringe. At 24 hours, 100 microliters of the
stock solution (50 g) containing 0.5 μ mg/mL Bro-
modeoxyuridine (BrdU) (BrdU, Sigma Chemical
Company, St. Louis, MO, USA) was added to
achieve a final concentration of 0.5 g/mL. After μ
the BrdU addition the culture tubes were covered
with light resistant paper and incubated for 72
hours at 37°C. After 70 hours, colchicine (0.2 / μ
mL) was added.Two hours after the addition of
colchicine (Colchicine powder, Sigma chemical
CO, St. Louis, MO, USA) (at 72nd hours), the
culture tubes were removed from the incubator.
After standard harvesting procedures, slides were
stained by the fluorescence plus Giemsa (FPG)
method
18 using Hoechst 33258 dye exposure to
fluorescent black light and Giemsa staining. EveryBanu Gürkan Köseoğlu, et al.
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point of exchanges was counted as a SCE:
terminal exchanges were scored as one SCE and
interstitial ones as two SCEs (Fig. 1). The fre-
quencies of SCE per metaphases before and after
treatment for each individuals were evaluated. In
this study, a statistical analysis was performed
using the Kruskal Wallis and Wilcoxon tests to
compare the percentage of SCE in different
sample groups, which were calculated with the
Graph Pad Prisma V.3 computer programme.
RESULTS
The SCE frequency per metaphase was calcu-
lated in all patients and compare within each
group before and after 3 days of medication.
These findings are shown in Table 1. In the Etol
group, the SCE frequencies were 8.65 ± 1.56 and
8.83 ± 1.40 before and after treatment, respectively.
The corresponding frequencies for the nimesulid
and naproxen groups, were 9.49 ± 1.42 and 9.59 ±
1.44, and 8.8 ± 1.27 and 8.84 ± 1.14 respectively
(Fig. 2). When all groups were combined, the SCE
frequencies per metaphase were 8.93 ± 1.41 and
9.08 ± 1.33 before and after NSAIDs treatment,
respectively. There was no statistically significant
difference in the frequencies of SCE between the
preoperative and postoperative values of the
etodolac (W = - 21; p = 0.32), nimesulid (W = - 11;
p= 0.62) and naproxen sodium (W = - 4; p = 0.82)
groups. The differences between the groups
before the treatment (KW = 1.69; p = 0.42) were
found to be statistically insignificant. The dif-
ference between the groups (KW = 2.19; p = 0.33)
after the treatment was also not significant (Table
2).
DISCUSSION
Cytogenetic markers, such as chromosomal
aberrations (CAs), and micronuclei (MN), and
SCE, are among the most widely used in the
indication of the early biological effects of DNA
damaging agents. In addition to cytogenetic
markers, various molecular genetic techniques,
including the Commet assay, have been used in
the evaluation of mutagenicity / carcinogencity.
The main difference between cytogenetic analysis
and the Commet assay is the kind of changes
detected. The Commet assay can detect repairable
defects or alkali labile sites, whereas cytogenetic
analysis can detect only chromosomal aberrations
that have occurred at least one cell cycle earlier.
19
Sister Chromatid Exchange can be defined as
the exchange of parts between sister chromatids.
20
Although the mechanism is not well understood,
21
SCE is thought to occur during the replication
process, and is accepted as a reliable test for the
evaluation of DNA damage.
22,23 Viral infections,
22
cigarette smoking,
24 advanced age,
25,26 malignant
diseases,
27 medications
10,11,12,28 and UV light
20,26
have all been shown to increase the frequency of
Fig. 1. In the normal state, one of the sister chromatids
is stained dark, while the other is stained light. When a
reciprocal change occurs, a dark segment and its homolo-
gue light counterpart change places leading to alternating
dark and light regions throughout the chromatids.
Fig. 2. Comparison of sister chromatid exchange frequ-
encies was performed between the preoperative and
postoperative values for etodolac, nimesulid and naproxen
sodium.Table 1. Demographic Data and Frequency of Sister Chromatid Exchanges per Metaphases
Patient
no.
Age
(yrs)
Sex
The frequency of SCE per
metaphases before treatment
The frequency of SCE per
metaphases after treatment
Etodolac group 1 21 M 7.8 8.1
2 23 F 6.8 7.2
3 25 M 8.9 9.2
4 22 F 11.1 10.2
5 21 M 10.9 11
6 19 F 9.8 10.2
7 21 M 8.8 7.9
8 18 M 7.4 7.6
9 19 F 8.2 9.7
10 19 M 6.8 7.2
Nimesulide group 11 18 M 11 11.1
12 22 F 10.5 12.2
13 23 M 11.8 10.3
14 21 F 9.8 9.9
15 19 M 7.8 8.7
16 22 M 7.6 7.8
17 23 F 9.8 9.4
18 21 F 9.4 9.6
19 25 F 7.8 7.4
20 21 F 9.4 9.5
Naproxene sodium 21 21 M 7.8 8.2
22 22 M 6.8 7.1
23 23 F 8.9 9.2
24 22 M 11.1 11
25 21 F 9.8 9.2
26 23 F 7.8 7.4
27 25 F 9.2 9.2
28 23 M 9.9 9.8
29 22 F 7.9 8.4
30 23 M 8.8 8.9
SCE, sister chromatid exchange; M, male; F, female.
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SCE.
In the present study, the in vivo genotoxicities
of three NSAIDs, namely etodolac, nimesulid and
naproxen sodium, were evaluated by SCE in
peripheral blood samples. Although the geno-
toxicities of other NSAIDs have been evaluated in
various studies,
9-12 according to our knowledge,
this is the first report of genotoxicity studies for
etodolac and nimesulid with the use of an in vivo
SCE assay.
Kullich and Klein
10 reported no increase in the
frequencies of SCE after 2 weeks of treatment with
various NSAIDs, including diclofenac, flurbipro-
fen, ibuprofen, indomethacin, isoxicam, ketopro-
fen, piroxicam, pirprofen, and tiaprofenic acid. A
study on rat bone marrow cells revealed a weak
genotoxic effect of the non-selective COX2
inhibitors ibuprofen, ketoprofen and naproxen
sodium.
11
Özkul et al.
12 reported a slight statistically
insignificant increase in the frequency of SCE with
the use of naproxen sodium.
In our study, the average SCE frequency per
metaphase was slightly higher after treatment,
without reaching statistical significance. Also, the
short term use of selective (etodolac) and non-
selective NSAIDs (nimesulid and naproxen sodium)
were not associated with any genotoxic effect that
could be detected using the SCE method in
peripheric lymphocytes.
It is concluded that in the short term thera-
peutic application of these drugs there are no
genotoxic effects on the chromosomes of peripheral
blood lymphocytes. However, further studies will
be required to understand the possible genotoxic
effects of their long-term use.
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